Recombinant human parathyroid hormone - GC Pharma

Drug Profile

Recombinant human parathyroid hormone - GC Pharma

Alternative Names: rhPTH - GC Pharma

Latest Information Update: 07 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Green Cross
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 06 Jul 2010 Discontinued - Phase-II for Osteoporosis in Germany (unspecified route)
  • 31 May 2006 Recombinant human parathyroid hormone has been licensed to BDD/CCDRD Group in regions outside Asia
  • 29 Jul 2005 Phase-II clinical trials in Osteoporosis in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top